Amgen Seeks U.K. Ban On Biosimilar Interchangeability With Innovator Product
Amgen has won the support of several U.K. legislators who are advocating a ban on the automatic substitution of innovator biopharmaceuticals, but it appears unlikely the British government will impose such a prohibition
You may also be interested in...
The Novartis subsidiary's epoetin alfa follow-on Binocrit, which received European marketing approval Aug. 31, will be priced at a 25 to 30 percent discount to innovator products, Sandoz exec Ajaz Hussain tells "The Pink Sheet." The first launch will be in Germany in September. Sandoz is maintaining its lead in biosimilars; Binocrit is the first approval for biosimilar EPO, although positive opinions have been issued for products from Hexal Biotech Forschungs (another Novartis business unit) and Medice Arzneimittel Putter. Sandoz was first to market with a biosimilar human growth hormone, Omnitrope (1"The Pink Sheet" June 5, 2006, p. 3)...
The interchangeability standard for follow-on biologics set out in Senate legislation creates a relatively smooth pathway for generic firms to seek approval of such products, but could also lead to an extended struggle to win acceptance for such products in the marketplace
Companies are racing to co-develop coronavirus treatments before finalizing deal teams. These team-ups raise questions about what happens after the pandemic subsides.